TEL AVIV, Israel--(BUSINESS WIRE)--Tikcro Technologies Ltd. (OTC BB: TIKRF), today announced the closing of the agreement to provide BioCancell Therapeutics, Inc., a clinical-stage biopharmaceutical company, with $2.5 million in funding to continue clinical trials of its drugs for the treatment of superficial bladder carcinoma, ovarian and pancreatic cancers.
